
AbbVie Shares Fall 6% Following Revenue Miss
By Sam Boughedda AbbVie (NYSE:ABBV) shares tumbled 6% Friday following its earnings report before the open, which beat earnings estimates but missed revenue expectations. The...
By Sam Boughedda AbbVie (NYSE:ABBV) shares tumbled 6% Friday following its earnings report before the open, which beat earnings estimates but missed revenue expectations. The...
AbbVie (NYSE:ABBV) reported Q2 EPS of $3.37, $0.03 better than the analyst estimate of $3.34. Revenue for the quarter came in at $14.58 billion versus the consensus estimate of $14.67...
Investing.com - AbbVie (NYSE:ABBV) reported on Friday second quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
(Reuters) – AbbVie Inc’s unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News...
The two largest U.S. oil & gas companies report earnings before markets open Friday along with a pharmaceutical and a consumer staples giant.
AbbVie (NYSE: ABBV) has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for Upadacitinib (RINVOQ) for the...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Britain Approves Global Blood Therapeutics' Sickle Cell Treatment U.K.'s Medicines and...
The CNBC Investing Club looks ahead to this week's busy earnings calendar, which includes results from Apple to Qualcomm.
By Daniel Shvartsman Investing.com - Central Banks and earnings will continue to dominate the week ahead. After the European Central Bank announced an unexpectedly hawkish 50 basis point...
Biopharmaceutical company AbbVie (NYSE: AABV) recently revealed that it has forged a partnership with eye care solutions provider iSTAR Medical SA to develop and commercialize the latter’s...
The Canadian regulatory authority, Health Canada has approved AbbVie’s (NYSE: ABBV) lead drug RINVOQ (upadacitinib, 15 mg), once-daily selective and reversible JAK inhibitor for the...
AbbVie Inc (NYSE: ABBV) announced a strategic transaction to develop and commercialize iSTAR Medical's MINIject device, a minimally invasive glaucoma surgical (MIGS) device. This...
Genmab A/S (NASDAQ: GMAB) has announced that AbbVie Inc (NASDAQ: ABBV) will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous...
By Michael Erman (Reuters) – Drugmaker AbbVie Inc generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim...
Company made most of its overall 2021 sales in the U.S. while recording most of its profits in foreign subsidiaries, leaving it with a tax bill far below the 21% U.S. rate.
By Sam Boughedda Morgan Stanley analyst Terence Flynn told investors in a note Friday that Genmab's (NASDAQ:GMAB) announcement of its intent to submit a biologics license application (BLA)...
Currently, Rinvoq approved for use in the EU in patients with moderate to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to...
We're raising cash about equal to what we put to work last Friday in three trades when the market was much lower.
AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Addex Stops Parkinson's-Associated Dyskinesia Trial Addex Therapeutics Ltd (NASDAQ: ADXN)...
Johnson & Johnson (NYSE: JNJ) and AbbVie Inc (NYSE: ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab...
By Michael Erman (Reuters) – Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin lymphoma in check...
By Yasin Ebrahim Investing.com – The Dow slumped Friday, closing out a brutal month for stocks as wave of big tech earnings this week failed to coax the bulls out of hiding. The Dow Jones...
By Yasin Ebrahim Investing.com – The S&P 500 fell Friday, as bearish bets on the tech sector resumed, paced by a rout in Amazon after the e-commerce giant reported its first quarterly loss...
By Sam Boughedda Investing.com -- U.S. equities are declining before the weekend, with the NASDAQ down over 1.5% midday. Here's what's moving at the midway point on Friday, April...
By Sam Boughedda Investing.com -- AbbVie Inc (NYSE:ABBV) stock is down more than 9% in early Friday trading after the company missed revenue expectations. The company reported...
AbbVie (NYSE:ABBV) reported Q1 EPS of $3.16, $0.02 better than the analyst estimate of $3.14. Revenue for the quarter came in at $13.54 billion versus the consensus estimate of $13.63...
Investing.com - AbbVie (NYSE:ABBV) reported on Friday first quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
By Geoffrey Smith Investing.com -- Stocks are set to end April on a negative note as disappointing updates from Amazon (NASDAQ:AMZN), Apple (NASDAQ:AAPL) and Intel (NASDAQ:INTC) weigh on...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Consumer Services, Basic Materials and Technology sectors propelled shares higher. At the close in NYSE,...
By Sam Boughedda Investing.com -- Shares of AbbVie Inc (NYSE:ABBV) fell 5% in Wednesday's session after the announcement that Vice Chairman and President Michael Severino would be...
By Sam Boughedda Investing.com -- U.S. indices are trading positively Wednesday, with the Nasdaq the biggest mover around lunchtime at +1.45%. Here are the midday movers on Wednesday, April...
Investing.com - AbbVie (NYSE:ABBV) reported on Wednesday fourth quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that fell short of expectations. AbbVie announced...
By Peter Nurse Investing.com - U.S. stocks are seen opening higher Wednesday, with the technology-focused Nasdaq index likely to outperform on the back of impressive quarterly earnings...
By Geoffrey Smith Investing.com -- The world's largest oil exporters meet to decide production quotas for March. Whether they can live up to them is another matter. Alphabet (NASDAQ:GOOGL)...
By Sam Boughedda Investing.com — Shares of AbbVie Inc (NYSE:ABBV) rose 1.8% Friday after the company's arthritis drug was approved by the U.S. Food and Drug Administration. The drug,...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, November 16th. Please refresh for updates. Walmart (NYSE:WMT) stock rose 0.7% after the retail giant raised...
By Dhirendra Tripathi Investing.com – AbbVie stock (NYSE:ABBV) climbed more than 4% Friday after the drugmaker raised its dividend, and also lifted its outlook for annual profit for...
Investing.com - AbbVie (NYSE:ABBV) reported on Friday third quarter {{erl-40041||earnings that beat analysts' forecasts and revenue that topped expectations. AbbVie announced earnings per...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.